Table 2.

Characteristics at kidney graft biopsy and pathological diagnosis

Patients	n = 20
Months after COVID-19	2 (1.4–3.5)
sCr at biopsy, mg/dL	1.5 (1.4–2.4)
Δ sCr, basal-biopsy, mg/dL	0.7 (0.2–1.3)
Δ sCr, COVID diagnosis-biopsy, mg/dL	− 0.28 (− 1.1 to + 0.02)
Persistent kidney dysfunction	7 (35)
Tacrolimus, ng/ml	6.4 (5.2–7.6)
PRA I, %	4 (0–17)
PRA II, %	10 (2–19)
De novo DSA	11 (55)
Class I	2 (10)
Class II	6 (30)
Class I & II	3 (15)
Kidney biopsy
Glomeruli	21 (10–27)
Diagnosis
No major abnormalities	6 (30)
Borderline for acute TCMR	2 (10)
Chronic active TCMR	1 (5)
Active ABMR	3 (15)
Mixed ABMR/TCMR	4 (20)
Chronic active ABMR	4 (20)

Values stated in n (%), median (25–75%) or mean ± sd

Δ delta, ABMR antibody mediated rejection, COVID-19 coronavirus disease-19, sCr serum creatinine, DSA donor-specific antibodies, MMF mycophenolate mofetil, PRA panel reactive antibody, TCMR T-cell mediated rejection